RxDoctor Payments Data

John Dalena, MD

Gastroenterology · Florham Park, NJNPI 1215944582

Payments from drug & device makers

$7,974in general payments, 2019–2025

Across 523 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Pfizer$807
  • Bristol Myers Squibb$576
  • Ironwood Pharmaceuticals, Inc$517
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$7,949100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,974 in reported general payments places this provider in the 80th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$281,468
Medicare patients
1,184
Services billed
2,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab15$115,295
CreonLipase/Protease/Amylase37$105,955
Humira PenAdalimumab12$81,738
Mesalamine79$64,650
XifaxanRifaximin15$36,726
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates535$35,450
LinzessLinaclotide38$28,789
Dexlansoprazole DrDexlansoprazole48$21,440
PentasaMesalamine18$21,190
Ursodiol35$7,695
Pantoprazole Sodium237$4,133
Balsalazide Disodium19$3,674
Colestipol Hcl25$3,385
Esomeprazole Magnesium78$3,326
SutabSod Sulf/Pot Chloride/Mag Sulf17$2,728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,728$134,74375 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,074$36,72615 claims
Braintree Laboratories, Inc.Sutab$156$2,72817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Florham Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →